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ABSTRACT
Objective: The objective of the study was to assess the effectiveness of alternative strategies
of malaria chemoprophylaxis on the reduction of malaria episodes and prevalence of
parasitaemia among pregnant women in Kigoma urban district in western Tanzania.
Design: Randomised antimalarial prophylactic trial.
Setting: The study was conducted in an urban maternal and child health (MCH) clinic in
Kigoma town.
Subjects: All pregnant women attending antenatal care services at Kigoma urban MCH
clinic were eligible. Informed consent was sought from each pregnant woman for participation
in the study.
Intervention measures: The intervention measures were intermittent and continuous malaria
chemoprophylaxis using chloroquine and proguanil.
Main outcome measures: Reduction of malaria episodes and parasitaemia and haemoglobin
levels among participating pregnant women in Kigoma urban district.
Results: Baseline data indicates that the overall mean haemoglobin concentrations among the
primigravidae and multigravidae women were similar within the intervention and comparison
groups (F-test (df= 5, N = 701) = 1.27, P = 0.27). Similarly, no significant difference was
observed in the prevalence of malaria parasitaemia within the primigravidae intervention
and comparison groups (χ2  test (df=5, N = 701) = 5.4, P = 0.4). Hence, the process of
randomisation produced comparable intervention and comparison groups with balanced
characteristics. Specific results of the baseline studies are presented in the companion paper.
Conclusion: We conclude that the process of randomisation resulted in comparable
intervention and comparison groups. As malaria is a common cause of considerable
morbidity and mortality among pregnant women in Tanzania, the present study provided
useful data for improving reproductive health in Kigoma region, western Tanzania.
INTRODUCTION
The Tanzanian Ministry of Health estimates that
malaria in Tanzania accounts for 4-5% of all deaths
occurring among patients admitted in hospitals. The very
high mortality rate attributable to malaria suggests the
public health importance of the disease in Tanzania. The
clinical effects of malaria among the highly vulnerable
groups such as pregnant women and young children have
been well documented in several studies(1-6). The studies
have indicated that malaria in pregnancy is often associated
with increased risk of severe anaemia, abortion, intrauterine
foetal death and low birth weight. To alleviate the
consequences of malaria on the health status of pregnant
women and their unborn children, regular administration
of safe and effective drugs against malaria has been
recommended throughout the course of pregnancy (1, 7).
However, since the severity of malaria has been shown to
decrease with increasing number of pregnancies(3-4),
there is a need to evaluate novel approaches for protecting
pregnant women from the ill effects of malaria taking into
account the documented differences in malaria immunity.
Studies conducted in Tanzania have shown that
chloroquine is still a useful drug for treating malaria
among pregnant women(8) and that proguanil (Paludrine®)
is a better malaria chemoprophylactic drug as compared
with chloroquine(9). In recognition of the health benefits
of malaria chemoprophylaxis among pregnant
women(5,7,9-12), the Tanzanian Ministry of Health
recommends continuous weekly chloroquine
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chemoprophylaxis for all pregnant women regardless of
maternal age, gravidity or parity. This policy suggests the
need for research programmes for evaluation of alternative
strategies for protecting pregnant women against malaria.
The present research project envisaged to test three
alternative approaches of protecting pregnant women
against malaria within the existing primary health care
delivery system in Kigoma urban district. The ultimate
aim of the project was to determine a simplified and cost-
effective chemoprophylaxis method that might be
recommended to the Ministry of Health for possible
change in the current guidelines on malaria prophylaxis
among pregnant women in Tanzania. Furthermore, the
results of this research programme might be useful within
the primary health care delivery system taking into account
the socio-economic constraints obtainining in a poor
resource country like Tanzania. In this paper, we present
the rationale and study design used in evaluating the
proposed alternative strategies of malaria prophylaxis
among pregnant women in an area assumed to have low
incidence of chloroquine resistant P. falciparum malaria.
The study was implemented in Kigoma urban district in
western Tanzania from September 1992 to January 1995.
Rationale and hypothesis of the study: There is no
doubt that for a pregnant woman, malaria poses a greater
hazard than any of the prophylactic drugs currently
advocated. This means that to improve reproductive health,
administration of malaria chemoprophylaxis to pregnant
women throughout the course of their pregnancy and the
first month of the puerperium is extremely important.
However, the strategies need to take into account the
proven differences in malaria severity among pregnant
women(3). Primigravidae are more susceptible to severe
form of malaria compared to multigravidae. Proguanil
(Paludrine®) is undoubtedly a very effective prophylactic
drug(9,10) but the cost of procuring proguanil in private
pharmacies is beyond the financial ability of many pregnant
women in Tanzania. Furthermore, the potential risk of
encouraging the emergency and spread of parasite
resistance to proguanil preclude wider use of proguanil
among pregnant women while maintenance of compliance
with continuous chemoprophylaxis using chloroquine may
be a major problem(13).
These problems have lead to a number of research
questions such as whether continuous malaria
chemoprophylaxis provides an additional benefit in semi-
immune multigravidae if chemotherapy is readily available,
that is to say,  giving treatment only when the pregnant
women become ill with malaria. It appears that protection
of pregnant women against malaria would be simplified
by adopting intermittent chemoprophylaxis for all pregnant
women if intermittent chemoprophylaxis gives similar
protection as continuous chemoprophylaxis. Although
intermittent prophylaxis may not be necessarily cheap, it
is an attractive novel approach for increasing compliance
while at the same time reducing drug pressure on malaria
parasites in Tanzania. Three intervention strategies were
evaluated using a cohort of 360 primigravidae and a
similar number of multigravidae using different
interventions (Table 1). Therefore, the aim of the study
was to determine whether the three intervention strategies
had different effect on malaria protection among pregnant
women in Kigoma urban district in western Tanzania.
MATERIALS AND METHODS
Study site and population: Kigoma urban district was
selected for the study in order to minimise the likelihood of
interaction of P.falciparum resistance with the proposed
interventions. Presence of high level of malaria resistance to
chloroquine could potentially interfere with the evaluation of the
effectiveness of the proposed chemoprophylaxis regimens. This
was borne out of the fact that occurrence of chloroquine resistant
P.falciparum malaria decreases with increasing distance as one
moves away from Dar es Salaam to the western part of
Tanzania(14). The research was conducted at an urban antenatal
care clinic which serves a catchment population of approximately
85,000 people in Kigoma/Ujiji town(15). Kigoma town is located
on the shores of Lake Tanganyika about 1300 kilometres west of
Dar es Salaam while Lake Tanganyika is formed within the
western part of the Great East African River Valley. Kigoma
town is the main transit port for cargo and passenger vessels run
by the Tanzania Railways Corporation to neighbouring countries
of Burundi and the Democratic Republic of Congo (formerly
Zaire). Kigoma/Ujiji township is surrounded by several fresh
water bodies including valleys around Luiche river which drains
into Lake Tanganyika. The mean annual rainfall for the Kigoma
region is approximately 1000 millimetres with dry season running
from July to September and has a high relative humidity.
Consequently malaria transmission in Kigoma region occurs
throughout the year.
According to the Regional Annual Health Report of 1989,
malaria accounted for 10-15% of all outpatient attendances and
46% of all admissions in Kigoma region(16). This figure places
malaria among the top ten causes of ill health in Kigoma region.
At the present time there is no specific malaria control programme
being undertaken in Kigoma region except for the chemotherapy
which is routinely given to patients suffering from clinical
malaria. Provision of malaria treatment is within the framework
of the World Health Organisation tactical variant number II for
malaria control(7).
Description of the treatment arms: Primigravidae group 1
(P1) and multigravidae group 1 (M1) received the gold standard
for malaria chemoprophylaxis using 100 mg of Paludrine® daily
while primigravidae group 2 (P2) and multigravidae group 2
(M2) received a full course of intermittent supervised periodic
malaria treatment using chloroquine at pre-determined time
periods (Table 1). The rationale for this being that sometimes
pregnant women forget to take the drugs on weekly basis which
often leads to increased risk of developing malaria. Since the
total dose of chloroquine (1200 mg) taken in four weeks for
continuous malaria chemoprophylaxis is approximately equal to
curative dose of malaria administered in three days at one-month
interval, intermittent chemotherapy may improve compliance
and could offer better protection than continuous chloroquine
chemoprophylaxis. The standard 300 mg of chloroquine base
taken weekly was used for group 3 primigravidae (P3) as
recommended by the Tanzanian Ministry of Health while the
semi-immune multigravidae group 3 (M3) received an initial
curative dose of chloroquine treatment and thereafter were
treated for malaria if they developed clinical malaria in the
course of their pregnancy (Table 1). The reason for evaluating
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the protective efficacy of chemotherapy in multigravidae  group
3 (M3) was that if chemotherapy alone in semi-immune
multigravidae is as effective as continuous chemoprophylaxis,
then protection of multigravidae will be simplified through the
provision of effective supervised periodic malaria treatment for
multigravidae. In addition to the strategies being tested, all the
study participants (primigravidae and multigravidae) were given
folic acid and ferrous sulphate tablets in accordance with the
such as breast enlargement. The cut-off point of 24 weeks of
gestation for inclusion into the study was determined through
history given by the pregnant women (last date of menstrual
period) and physical examination. The categorisation of pregnant
women having their first and second pregnancies into one group
was based on the assumption that in Tanzania the majority of
women having their first and second pregnancies do not differ
significantly in terms of age and other obstetric parameters.
Table 1
Regimens evaluated for malaria prophylaxis among pregnant women in Kigoma urban district, western Tanzania.
Group Chemoprophylaxis regimens
Primigravidae (gravidae 1 & 2)
Continuous prophylaxis* First visit: Curative dose of chloroquine (1500 mg
with proguanil (Group P1) CQ base in 3 days), and thereafter a daily dose of 100  mg
proguanil until 4 weeks after delivery.
Intermittent prophylaxis First visit: Curative dose of chloroquine (1500 mg CQ
with chloroquine (Group P2) base in 3 days), and thereafter curative doses of CQ
at 20, 24, 28, 32, and 36 weeks of gestation.
Continuous prophylaxis with First visit: Curative dose of chloroquine (1500 mg CQ base in
chloroquine (Group P3) 3 days), and thereafter  300 mg weekly until 4 weeks after delivery
Multigravidae (gravidae 3 or more).
Continuous prophylaxis* First visit: Curative dose of chloroquine (1500 mg CQ base in
with proguanil (Group M1) 3 days) thereafter, daily doses of praguanil 100 mg until
4 weeks after  delivery.
Intermittent prophylaxis First visit: Curative dose of chloroquine (1500 mg
with chloroquine (Group M2) CQ base in 3 days) thereafter curative doses of CQ
at 20, 24, 28, 32, and 36 weeks of gestation.
Chemotherapy only with First visit: Curative dose of chloroquine (1500 mg
chloroquine (Group M3) CQ base in 3 days) thereafter treatment when ill with a positive
malaria blood slide.
CQ = Chloroquine; *This regimen was assumed to be the gold standard for malaria chemoprophylaxis
Tanzanian Ministry of Health policy on prevention of anaemia
in pregnancy. It was assumed that supplementation with folic
acid and ferrous sulphate tablets would not have any interaction
with the anti-malarial drugs except for the recently reported risk
of increasing malaria incidence in the supplementation group(17-
19).
Eligibility criteria: Eligibility for enrolment of pregnant
women into the study included permanent residence in Kigoma
town and the surrounding neighbourhoods. Exclusion criteria
included history of allergic reaction to the drugs to be used in the
study and pregnancy of more than 24 weeks (6 months) of
gestation. For the purpose of this study, a pregnant woman was
defined as any woman who had missed her menstrual periods for
three months or more and had in addition, other signs of pregnancy
Randomisation: Two senior nursing officers and one senior
medical laboratory technologist from Maweni Regional Hospital
were recruited into the study as resident researchers responsible
for data collection in Kigoma. The researchers were given one-
week training workshop on how to carry out specific components
of the study including the process of randomisation and follow
up. The anti malarial prophylactic regimens used were written on
cards which were placed inside special envelopes prepared for
the study. The envelopes were identifiable only by P or M series
written on them (P standing for primigravidae and M for
multigravidae). In order to ensure balanced allocation to the
regimens, equal number of cards for each regimen in the P and
M series were prepared, that is, 120 cards for each regimen to
make a total of 360 cards for P series and similar number of cards
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for M series. The envelopes were placed in two separate boxes,
one box for P and another for M series.
The objectives and study procedures were fully described
to the women before asking for their verbal informed consent for
participation in the study. The details included description of
measurements to be taken during the study and anticipated
benefits to the study participants. In addition, all the women were
informed that they had the liberty to refuse participation in the
study and that refusal to participate had no negative implications
whatsoever on the quality of antenatal care services to those who
refused to participate in the study. Allocation of the pregnant
women to the various interventions was in accordance with the
reported number of pregnancies for each woman. Therefore, any
primigravida consenting to participate in the study was
randomised to the chemoprophylaxis regimens denoted by P 1,
P2, and P3 while multigravidae were randomised to regimens
denoted by M1, M2 and M3. Pregnant women attending antenatal
care at the selected urban maternal and child health (MCH) clinic
in Kigoma town and who consented to participate in the study
were enrolled into the study consecutively until a total sample
size of 720 pregnant women was attained. Detailed analyses of
the baseline data are presented in the companion paper. The
senior nursing officers performed the process of randomisation
by picking up one envelope from previously shuffled P or M
series envelopes. Allocation of each subject to the appropriate
chemoprophylaxis regimen was made after opening up the
envelope and reading the chemoprophylaxis regimen written on
the card. Each consenting participant underwent baseline studies
immediately after randomisation was achieved. The baseline
studies included estimation of haemoglobin levels and
haematocrit, sickling test, blood slide for malaria parasites as
well as testing for the presence of antimalarial metabolites in
urine (Figure 1). Sickle cell trait was tested at baseline in order
to permit assessment of potential modifying effect of sickle cell
trait on the occurrence of malaria parasitaemia during data
analysis(20). All the tests were carried out at Maweni Regional
Hospital in Kigoma by a senior medical laboratory technologist
who was responsible for all the laboratory examinations needed
for the study.
Follow up studies: Pregnant women were followed up at
monthly intervals up to two months of puerperium to determine
the effect of the interventions on haemoglobin levels, birth
weight, occurrence of malaria and other important parameters
indicated in Figure 1. Any woman who became anaemic or
developed malaria during the course of the study was offered
treatment at the clinic or if complicated the patient was referred to
Maweni Regional Hospital for appropriate management. The field
team was responsible for follow up of all pregnant women who did
not come to the clinic as advised on the their cards. The field team
filled out a separate questionnaire for each woman who did not
come for follow up and reasons for not coming for follow up. In
addition, there was a separate follow up questionnaire designed to
assess use of other preventive measures against malaria such as
bednets, mosquito coils, and self-medication. These malaria
preventive measures were closely monitored because they could
potentially confound the effect of the proposed strategies on
malaria protection. Similarly, other factors that may affect birth
weight such as high blood pressure, twin pregnancy, and maternal
workload were investigated. However, seasonal variation in malaria
transmission was not assessed because the studies were running
across all the seasons of the year.
The following measures were taken in order to ensure that
the cohorts began at a known starting point. Firstly, baseline data
on haemoglobin levels, haematocrit, malaria parasitaemia, and
helminthic infestation were taken. Secondly, all women were
treated for malaria using the standard chloroquine regimen
recommended by the Tanzanian Ministry of Health to ensure that
all women were free from any asymptomatic malaria infection.
This was important in order to assess with reasonable certainty
that any malaria episode occurring during the follow up period
was due to new infections. Similarly, all pregnant women found
to be infected with helminths were given appropriate treatment
except antischistosomal treatment that is not normally
recommended in pregnancy. The women were advised to come
to the clinic for treatment any time they developed fever. Use of
standby anti malarial drugs for self-medication was allowed
provided the women reported to the clinic on the following day
for a thorough check up and a blood test for malaria parasites.
Any fever that responded well to the use of standby anti malarial
drugs was interpreted to be due to malaria even if a subsequent
blood test for malaria parasites was negative. Finally, all women
were advised to deliver their babies in Maweni Regional Hospital
in Kigoma. At delivery the field team was responsible for taking
the following measurements: birth weight, placental smear for
malaria parasites, and detection of congenital defects or
malformations (Figure 1).
Figure 1
Follow up design and outcome variables among pregnant women in Kigoma urban district, western Tanzania
Cohorts Methods of regimen Monthly follow up Outcome measures
allocation measurements taken at delivery
Randomised to P1, P2 or P3
Primigravidae Baseline data Haemoglobin
Haemoglobin Malaria fever
Blood slide Blood slide Incidence of malaria
Sickling test Body weight Low birth weight
Multigravidae Haematocrit Side effects Placental infection
Stool exam Urine for CQ Miscarriages
Urinalysis Haematocrit
Blood pressure Foetal growth
Randomised to M1, M2 or M3
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Ethical considerations: The project was reviewed and
approved by the ethical committee of the Muhimbili University
College of Health Sciences. There were no serious ethical
problems because all the drugs used in the study are approved in
Tanzania and there was no placebo group. The only issues to be
considered involved the discomfort and inconveniences that
could arise during the process of taking blood samples for
estimation of haemoglobin levels, haematocrit and blood tests
for malaria parasites as well as stool and urine examinations for
helminths.
Sample size: The incidence of malaria among pregnant
women in Kigoma was not known at the time of planning the
study. To calculate sample size we used data reported from
studies conducted in Kenya which had shown that the prevalence
of malaria parasitaemia among pregnant women receiving
chemoprophylaxis was 17.7% compared to 26.2% among those
not receiving any form of chemoprophylaxis(21). The target of
the study was to reduce the prevalence of malaria parasitaemia
by more than 50%, that is,  reducing the prevalence of parasitaemia
from 26.2% to 10%. Using the statistical formula proposed by
Fleiss(22) for calculating sample sizes in epidemiological studies
with statistical power set at 80%, the number of pregnant women
required for the study was estimated to be 670, that is,
approximately 111 pregnant women for each of the six proposed
intervention groups. However, the sample size was approximated
to 720 pregnant women (about 120 pregnant women per
intervention) in case a large proportion of the participants could
decide to drop out of the study after enrolment.
Outcome measures: The primary outcome measure of
interest was the occurrence of malaria among the women receiving
the various chloroquine regimens as compared to the women
receiving proguanil. Additional endpoints were abortion, low
birth weight, and placental malaria parasitation (Figure 1).
Proguanil regimen was used as the gold standard for malaria
prophylaxis in pregnant women and the other chemoprophylaxis
regimens as comparison groups in order to avoid the ethical
problem of using placebo group. Use of placebo group was not
acceptable as it would have denied some pregnant women a
proven protective measure against malaria. The comparison
regimens were considered effective if they reduced the incidence
of malaria episodes and of placental infection at a similar level
as proguanil malaria prophylaxis regimen. Although folic acid
and ferrous sulphate were given to prevent anaemia, the incidence
and prevalence of anaemia in pregnancy as well as the incidence
of low birth weight babies were also assessed.
Data management: All completed questionnaire forms
were checked for inconsistencies and illogical data. Data were
entered into a computer using statistical package for social
sciences (SPSS) version 5.0 while data analysis was conducted
using SPSS version 8 for Windows. Open-ended variables
were coded before data entry. Statistical data analysis was
performed using one-way analysis of variance (ANOVA) and
Chi-squared test for contingency tables. Results were considered
significant if P ≤ = 0.05. All P-values presented in this paper are
two-sided.
RESULTS
Comparability of the intervention and comparison
groups. Table 2 presents the distribution of malaria
parasitaemia and mean haemoglobin (Hb) concentrations
among the study groups. As can be seen in Table 2, there
was no significant difference in the overall prevalence
proportions of malaria parasitaemia between primigravidae
and multigravidae groups (9.8% versus 9.0%; χ2 (df = 1,
n = 701) = 0.81, P = 0.4). Likewise, there was no significant
difference in the observed prevalence proportions of
malaria parasitaemia within primigravidae intervention
and comparison groups (χ2 (df = 2, N = 391) = 0.67, P =
0.70). Similar observations were seen among multigravidae
intervention and comparison groups (χ2 (df = 2, N = 310)=
4.79, P = 0.1).
Table 2
Malaria parasitaemia and mean haemoglobin concentrations among the intervention and comparison groups in Kigoma urban district,
Western Tanzania
Malaria parasitaemia Haemoglobin levels (g/dl)
Predictor Sample size N (%)* P-value Range Mean (95% CI)**
Total series 701 65 9.3 5.9 - 14.9 10.1(9.9-10.2)
Intervention groups
Primigravidae groups
Proguanil prophylaxis(Pl) 135 15 11.1 P = 0.7 5.9-14.0 9.9 (9.6-10.3)
Intermittent CQ prophylaxis(P2) 131 11 8.4 6.3 - 13.0 9.9 (9.6-10.3)
Chloroquine prophylaxis(P3) 125 11 8.8 5.9 - 14.5 10.2 (9.8-10.4)
Total 391 27 9.8 5.9 - 14.5 10.0 (9.8 -10.2)
Multigravidae groups
Proguanil prophylaxis (Ml) 103 13 12.6 P = 0.1 6.3 -13.5 10.0 (9.7 - 10.3)
Intermittent CQ prophylaxis (M2) 99 4 4.0 5.9 -14.1 10.2 (9.9 -10.6)
Chemotherapy when ill (M3) 108 11 10.2 5.9-14.9 10.4 (10.1-10.7)
Total 310 28 9.0 5.9-14.9 10.2 (10.0-10.4)
CQ= Chloroquine; *Overall rates corrected χ2 (df = 1, N = 701) = 0.81, P = 0.4; **F-test (df = 5, N = 701) = 1.27, P = 0.27.
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The overall mean haemoglobin concentrations among the
primigravidae and multigravidae women were also
comparable within the intervention and comparison groups
(F-test (df = 5, N = 701) =1.27, P = 0.27). According to
Table 2, the overall mean haemoglobin concentration was
10.1 g/dl (range 5.9-14.9 g/dl) while the observed Hb
concentration among primigravidae women was 10.0 g/dl
(range 5.9 - 14.5 g/dl) and 10.2 g/dl (range 5.9-14.9 g/dl)
for multigravidae women.
DISCUSSION
Epidemiological studies conducted in malaria
holoendemic areas have demonstrated that malaria
chemoprophylaxis is significantly associated with reduced
incidence of severe anaemia and that of low birth weight
babies(3,5,23-25). Reduction in the incidence of low birth
weight babies may be due to the prevention of placental
dysfunction which is often associated with placental malaria
parasitisation (2,24). On the other hand, observations
from malaria vaccine trial conducted among Tanzanian
children in Ifakara district appear to be inconclusive(26)
and it may take several years before the safety and efficacy
of the new malaria vaccine is accepted for use among
pregnant women. Therefore, prevention of malaria among
pregnant women is still largely dependent upon
chemoprophylaxis until such time that a cheap and effective
vaccine will be available for use in poor resource countries
like Tanzania. Consequently, evaluation of potentially
new cost-effective interventions against malaria
particularly among vulnerable populations is still important.
The present study focused on evaluation of malaria
chemoprophylaxis among pregnant women using a
randomised trial design so as to generate data that will be
useful for improving reproductive health in Tanzania.
According to the data presented in this paper, randomisation
of the study subjects to the intervention and comparison
groups produced comparable groups with balanced
characteristics. Therefore, the objectives of randomisation
were achieved.
Nevertheless, it is important to appreciate the
difficulties implicit in the design and conduct of malaria
chemoprophylaxis field trials in an environment with
diverse ecological and socio-economic settings. The
existence of P. falciparum malaria resistance in most areas
of Tanzania may result in the failure to demonstrate
protective efficacy of any particular malaria
chemoprophylactic drug. Furthermore, there may be
problems in the ascertainment of compliance with the
recommended dosage of anti malarial drugs among
pregnant women. Studies conducted in Dar es Salaam
showed that because of high incidence of chloroquine
associated side effects, it was difficult for the pregnant
women to comply with the recommended dose of
chloroquine chemoprophylaxis(16). Therefore, failure to
comply with the recommended dosage of chloroquine
prophylaxis may result in poor protective effect among the
defaulters. However, in the present study compliance was
monitored through testing for chloroquine metabolites in
urine at each follow up visit at the MCH clinic in Kigoma
town. Therefore, it is highly unlikely that the participating
women did not comply with the recommended dose for
malaria prophylaxis. However, no attempt was made to
perform any biochemical tests to monitor compliance
rates among pregnant women who were receiving proguanil
regimen. This was omitted because there were no reports
indicating that proguanil had high non-compliance rates
similar to chloroquine.
A further difficulty in any prospective follow up
study is the likelihood of some participants choosing to
drop out of the study. One of the problems associated with
high attrition rates among the study participants is the
reduction in the statistical power of the study to detect the
difference in the trial groups. A more serious problem
associated with high attrition rate is bias which may occur
if those lost for follow up have different characteristics
from those still remaining in the study. However,
occurrence of high attrition rate was very unlikely because
enrolment was based on permanent residence in Kigoma/
Ujiji town and the surrounding neighbourhoods. Moreover,
the use of a randomised study design ensured that any
losses to follow up could probably occur in all the groups
and therefore give unbiased results.
Another likely problem in this study was the possibility
of mixing the effect of the chemoprophylactic regimens
being tested with the effect that might accrue from
concurrent utilisation of other proven malaria preventive
measures. The potential confounding factors include the
differential use of bednets, mosquito coils, and insecticides
among the trial groups. However, the process of
randomisation may have corrected for any differential
utilisation of any malaria preventive measures. Therefore,
the results are very unlikely to be biased. Finally, recent
studies indicate that supplementation with folic acid and
ferrous sulphate tablets increases the incidence of malaria
and other infectious diseases among those receiving
supplementation(17-19). It is felt that this had no effect on
impact evaluation because all the groups were given
supplementation and any increase in the incidence of
malaria would therefore occur in all the groups under
investigation.
In conclusion, the results from this study will provide
useful information for formulating policies towards
improving reproductive health in Tanzania. During data
analysis, careful adjustment for potential confounding
factors were made in order to improve quality of the data.
The interpretation of a positive result are straightforward
and include implications for changes in malaria
chemoprophylaxis policies while a negative result indicate
continued use of and strengthening of the existing malaria
prophylaxis regimens in Tanzania.
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